Max Gelman

RFK Jr. advisor Calley Means challenges drugmakers considering pulling their investment in the US over Trump's most favored nations plan, calling it 'morally reprehensible.'

Previously called STS101, the company said Wednesday that the drug’s brand name is Atzumi and is indicated for acute migraine with or without aura.

The fate of a small, privately-held biotech’s new drug has been delayed, in what appears to be a sign that broad cuts to the FDA by the Trump administration may ...

During Thursday’s first-quarter earnings call, Chris Boerner made his strongest comments yet that Bristol Myers intends to be active at the dealmaking table this year.

Sanofi is teaming up with a private biotech in Delaware on a pair of bispecific antibodies for autoimmune and inflammatory bowel diseases.

The Johnson & Johnson CEO subtly but assertively criticized the Trump administration’s plans for pharmaceutical tariffs, saying they are not an effective tool to onshore drug manufacturing to the US.

Trump announces upcoming pharma tariffs while Novartis pledges $23B US investment. Congressional commission urges $15B biotech investment to compete with China.

The fallout comes amid a yearslong slog for biotech, which has struggled since high interest rates and inflation curbed what was a booming market during the Covid-19 pandemic.

FDA faces major shakeup as CBER chief Peter Marks exits, Trump admin implements cuts across HHS, and new tariff plan creates industry confusion. Sens. Cassidy and Sanders seek answers.

FDA biologics chief Peter Marks resigns over vaccine dispute with HHS Secretary RFK Jr., causing biotech stocks to drop. Moderna down 11%, Sarepta down 7.5%, uniQure down 20%.

FDA approves Sanofi's RNAi hemophilia drug fitusiran, licensed from Alnylam, to treat both hemophilia A and B by lowering antithrombin protein levels.

Actinium Pharmaceuticals holds investor event at Trump's Mar-a-Lago resort, discussing Actimab-A and Iomab-ACT programs. CEO Sandesh Seth announces

Alnylam will likely face challenges in turning a profit this year, despite executives promising to do so. But the label for its newly-approved Amvuttra indication may give it an advantage over its rivals Pfizer and BridgeBio.

Alnylam's future profitability hinges on the ability to get Amvuttra prescribed as a first-line option in ATTR-CM, which is an increasingly competitive market led by Pfizer’s Vyndaqel/Vyndamax franchise and BridgeBio’s Attruby.

Trump administration withdraws Dave Weldon's CDC nomination, while Pfizer/Arvinas report mixed breast cancer data and Roche/Zealand Pharma form $5.3B obesity partnership.

A small-cap biotech developing gene therapies is spinning out its Parkinson’s disease program into a new company in partnership with a secretive AI startup co-founded by former Google CEO Eric Schmidt.

Senate hearings held for Trump's FDA nominee Marty Makary and NIH pick Jay Bhattacharya; AbbVie enters obesity market; Swiss biotech Asceneuron halts Alzheimer's trial.

Roche announced a new research hub on Friday in partnership with Harvard that it hopes will accelerate efforts in disease biology, engineering and AI.

A UK startup that wants to bring protein degraders to the neurodegeneration field has closed a $31 million seed round.

Biotech investing saw growth in 2024, with RA Capital leading VCs. FDA cancels flu vaccine meeting, Pfizer hires ex-FDA official Cavazzoni, and Bayer CEO Anderson discusses turnaround plans.